Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (29994)	1/9/2000 1:00:00 AM
From: Torben Noerup Nielsen	Read Replies (1) \| Respond to of 32384

A tidbit. Apparently, the industry average is a Price to Sales of around 20. If Ligand could get net sales of $100M of Targretin for lymphoma along with the other drugs out now, that would put their reasonable market cap at $2B. That implies a price increase by a factor of 3. Could that be done by year's end? If it can, the party is definitely on! Thoughts? Still trying to get a quantitative handle on this one. Thanks, Torben

To: Torben Noerup Nielsen who wrote (29994)	1/9/2000 2:06:00 AM
From: Skeeter Bug	Read Replies (1) \| Respond to of 32384

torben, i agree w/ your sentiments. i think the dr's point was that you couldn't rule out that these people got better for a reason other than targretan. i take a walk on tuesday and my cold is better on wednesday. did the walk cure my cold? bad example, but you know the point of it. you know all this. in this case the results were so amazing and extraordinary, imho, that a reasonable person would conclude targretin made a HUGE difference even without the data of a baseline group. what about those two clowns that said "no" for approval after hearing these stories? i'd think they s/b forced to express their "logic" in a public forum and be held accountable for their views.